
|Articles|January 28, 2022
What’s New?
Acne patients are benefitting from a robust pipeline with treatments that hold promise for increased efficacy and safety. First-in-class additions to the FDA-approved armamentarium, such as the novel antiandrogen clascoterone (Winlevi; Sun Pharma), give dermatologists and pediatricians new tools to combat this skin condition. Speakers offer insights on matching medications to individual patient needs and controlling costs.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Contemporary Pediatrics
1
FDA authorizes Avulux light-filtering lenses for migraine-associated light sensitivity in patients 12 and older
2
New multisociety position paper details hospital strategies to close gaps in sepsis care
3
FDA approves dolutegravir dispersible tablets for HIV-infected newborns
4
Lebrikizumab phase 3 data show improvements in atopic dermatitis symptoms, itch in children
5

